C4 Therapeutics Stock Piotroski F Score

CCCC Stock  USD 2.12  0.07  3.20%   
This module uses fundamental data of C4 Therapeutics to approximate its Piotroski F score. C4 Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of C4 Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about C4 Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out C4 Therapeutics Altman Z Score, C4 Therapeutics Correlation, C4 Therapeutics Valuation, as well as analyze C4 Therapeutics Alpha and Beta and C4 Therapeutics Hype Analysis.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
  
At this time, it appears that C4 Therapeutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
0.0
Piotroski F Score - Unavailable
Current Return On Assets

N/A

Focus
Change in Return on Assets

N/A

Focus
Cash Flow Return on Assets

N/A

Focus
Current Quality of Earnings (accrual)

N/A

Focus
Asset Turnover Growth

N/A

Focus
Current Ratio Change

N/A

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

N/A

Focus
Change in Gross Margin

N/A

Focus

C4 Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to C4 Therapeutics is to make sure CCCC is not a subject of accounting manipulations and runs a healthy internal audit department. So, if C4 Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if C4 Therapeutics' financial numbers are properly reported.

About C4 Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

About C4 Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:
Check out C4 Therapeutics Altman Z Score, C4 Therapeutics Correlation, C4 Therapeutics Valuation, as well as analyze C4 Therapeutics Alpha and Beta and C4 Therapeutics Hype Analysis.
For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.